Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

39.75 +0.48 (+1.22%)
Official Closing Price Updated: 4:10 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,623,693
Open 39.37
Bid (Size) 39.61 (9)
Ask (Size) 39.85 (9)
Prev. Close 39.27
Today's Range 39.37 - 39.76
52wk Range 33.67 - 43.84
Shares Outstanding 5,385,189,617
Dividend Yield 3.63%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages since 2020. Learn about challenges in medicine supplies, regulatory... 
Via Benzinga
Topics Brexit
Exposures Brexit
Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future
Anne Wojcicki, CEO of 23andMe mulls taking the genetics company private amid market challenges. With declining revenue and a focus shift to drug development, the move seeks funding for potential... 
Via Benzinga

Performance

YTD
+5.97%
+5.97%
1 Month
-6.07%
-6.07%
3 Month
+0.53%
+0.53%
6 Month
+12.32%
+12.32%
1 Year
+7.64%
+7.64%

More News

Read More
GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 Years
Via Benzinga
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Down 75%. Is Agenus Stock a Buy on the Dip?
Via The Motley Fool
Peering Into GSK's Recent Short Interest
Via Benzinga
CureVac, GS Partner Release Data On Influenza Vaccine Study
Via Benzinga
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Via MarketBeat
Exposures Product Safety
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
Via The Motley Fool
Russell 2000 Index Best And Worst Performing Stocks Of 2024
Via Talk Markets
Topics Stocks
Exposures US Equities
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
Via Investor's Business Daily
Exposures Product Safety
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
Via The Motley Fool
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
Via Benzinga
GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial Cancer
Via Benzinga
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B
Via Benzinga
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
From GSK plc
Via Business Wire
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
Via InvestorPlace
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
Via InvestorPlace
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
Via Benzinga
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Via InvestorPlace
GSK's Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage Study
Via Benzinga
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
From GSK plc
Via Business Wire
Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.